KDR and head and neck squamous cell carcinoma: The first report to evaluate a c-Met inhibitor in HNSCC was a phase II study which tested the efficacy, safety, and tolerability of single-agent foretinib, an ATP-competitive inhibitor of c-Met and VEGFR2, in patients with R/M HNSCC [131].